CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview-Reference-Cited by-同舟云学术

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

Published:2020-04-18 Issue:8 Volume:55 Page:1525-1532
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Mohty Mohamad,Dulery Remy,Gauthier Jordan^ORCID,Malard Florent^ORCID,Brissot Eolia,Aljurf Mahmoud,Bazarbachi Ali,Chabanon Christian^ORCID,Kharfan-Dabaja Mohamed A.^ORCID,Savani Bipin N.,Huang He,Kenderian Saad S.,Perales Miguel-Angel,Yakoub-Agha Ibrahim,Nagler Arnon

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-0892-7.pdf

Reference37 articles.

1. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

2. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

3. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250–9.

4. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498–505.

5. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw. 2016;14:196–231.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicités hématologiques après CAR-T cells, recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC);Bulletin du Cancer;2024-04

2. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update;Critical Care;2024-03-05

3. CAR-T treatment for cancer: prospects and challenges;Frontiers in Oncology;2023-12-05

4. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study;Leukemia & Lymphoma;2022-11-18

5. Transdifferentiation of high-grade B-cell lymphoma with MYC and BCL2 rearrangements into histiocytic sarcoma after CAR T-cell therapy: a case report;Journal of Hematopathology;2022-10-21